[HTML] nejm.org

[HTML][HTML] Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction

SD Solomon, JJV McMurray, B Claggett… - … England Journal of …, 2022 - Mass Medical Soc
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …
被引用次数：1410 相关文章

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

SD Solomon, JJV McMurray, B Claggett, RA de Boer… - 2022 - pubmed.ncbi.nlm.nih.gov
Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction

SD Solomon, JJV McMurray, B Claggett… - New England Journal …, 2022 - eprints.gla.ac.uk
Background: Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

SD Solomon, JJV McMurray, B Claggett… - New England Journal …, 2022 - cir.nii.ac.jp
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

SD Solomon, JJV McMurray, B Claggett… - New England Journal …, 2022 - research.rug.nl
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.

SD Solomon, JJV McMurray, B Claggett… - The New England …, 2022 - diva-portal.org
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

SD Solomon, JJV McMurray… - … England Journal of …, 2022 - publicum.umed.lodz.pl
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.

SD Solomon, JJV McMurray, B Claggett… - The New England …, 2022 - europepmc.org
Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

SD Solomon, JJV McMurray… - … England Journal of …, 2022 - publicum.umed.lodz.pl
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …